The purinergic system in allotransplantation

A. Vergani, S. Tezza, C. Fotino, G. Visner, A. Pileggi, A. Chandraker, P. Fiorina

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The purine nucleotide adenosine triphosphate (ATP) is a universal source of energy for any intracellular reaction. Under specific physiological or pathological conditions, ATP can be released into extracellular spaces, where it binds and activates the purinergic receptors system (i.e. P2X, P2Y and P1 receptors). Extracellular ATP (eATP) binds to P2X or P2Y receptors in immune cells, where it mediates proliferation, chemotaxis, cytokine release, antigen presentation and cytotoxicity. eATP is then hydrolyzed by ectonucleotidases into adenosine diphosphate (ADP), which activates P2Y receptors. Ectonucleotidases also hydrolyze ADP to adenosine monophosphate and adenosine, which binds P1 receptors. In contrast to P2X and P2Y receptors, P1 receptors exert mainly an inhibitory effect on the immune response. In transplantation, a prominent role has been demonstrated for the eATP/P2X7R axis; the targeting of this pathway in fact is associated with long-term graft function and reduced graft versus host disease severity in murine models. Novel P2X receptor inhibitors are available for clinical use and are under assessment as immunomodulatory agents. In this review, we will focus on the relevance of the purinergic system and on the potential benefits of targeting this system in allograft rejection and tolerance.

Original languageEnglish
Pages (from-to)507-514
Number of pages8
JournalAmerican Journal of Transplantation
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Adenosine Triphosphate
Purine Nucleotides
Transplantation Tolerance
Purinergic Receptors
Antigen Presentation
Extracellular Space
Graft vs Host Disease
Chemotaxis
Adenosine Diphosphate
Transplantation
Cytokines
Transplants
ectoATPase

Keywords

  • ATP
  • P2X7R
  • purinergic system
  • rejection

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Vergani, A., Tezza, S., Fotino, C., Visner, G., Pileggi, A., Chandraker, A., & Fiorina, P. (2014). The purinergic system in allotransplantation. American Journal of Transplantation, 14(3), 507-514. https://doi.org/10.1111/ajt.12567

The purinergic system in allotransplantation. / Vergani, A.; Tezza, S.; Fotino, C.; Visner, G.; Pileggi, A.; Chandraker, A.; Fiorina, P.

In: American Journal of Transplantation, Vol. 14, No. 3, 03.2014, p. 507-514.

Research output: Contribution to journalArticle

Vergani, A, Tezza, S, Fotino, C, Visner, G, Pileggi, A, Chandraker, A & Fiorina, P 2014, 'The purinergic system in allotransplantation', American Journal of Transplantation, vol. 14, no. 3, pp. 507-514. https://doi.org/10.1111/ajt.12567
Vergani A, Tezza S, Fotino C, Visner G, Pileggi A, Chandraker A et al. The purinergic system in allotransplantation. American Journal of Transplantation. 2014 Mar;14(3):507-514. https://doi.org/10.1111/ajt.12567
Vergani, A. ; Tezza, S. ; Fotino, C. ; Visner, G. ; Pileggi, A. ; Chandraker, A. ; Fiorina, P. / The purinergic system in allotransplantation. In: American Journal of Transplantation. 2014 ; Vol. 14, No. 3. pp. 507-514.
@article{cc7442be7c6947e4b99e137f3c6eedf9,
title = "The purinergic system in allotransplantation",
abstract = "The purine nucleotide adenosine triphosphate (ATP) is a universal source of energy for any intracellular reaction. Under specific physiological or pathological conditions, ATP can be released into extracellular spaces, where it binds and activates the purinergic receptors system (i.e. P2X, P2Y and P1 receptors). Extracellular ATP (eATP) binds to P2X or P2Y receptors in immune cells, where it mediates proliferation, chemotaxis, cytokine release, antigen presentation and cytotoxicity. eATP is then hydrolyzed by ectonucleotidases into adenosine diphosphate (ADP), which activates P2Y receptors. Ectonucleotidases also hydrolyze ADP to adenosine monophosphate and adenosine, which binds P1 receptors. In contrast to P2X and P2Y receptors, P1 receptors exert mainly an inhibitory effect on the immune response. In transplantation, a prominent role has been demonstrated for the eATP/P2X7R axis; the targeting of this pathway in fact is associated with long-term graft function and reduced graft versus host disease severity in murine models. Novel P2X receptor inhibitors are available for clinical use and are under assessment as immunomodulatory agents. In this review, we will focus on the relevance of the purinergic system and on the potential benefits of targeting this system in allograft rejection and tolerance.",
keywords = "ATP, P2X7R, purinergic system, rejection",
author = "A. Vergani and S. Tezza and C. Fotino and G. Visner and A. Pileggi and A. Chandraker and P. Fiorina",
year = "2014",
month = "3",
doi = "10.1111/ajt.12567",
language = "English",
volume = "14",
pages = "507--514",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The purinergic system in allotransplantation

AU - Vergani, A.

AU - Tezza, S.

AU - Fotino, C.

AU - Visner, G.

AU - Pileggi, A.

AU - Chandraker, A.

AU - Fiorina, P.

PY - 2014/3

Y1 - 2014/3

N2 - The purine nucleotide adenosine triphosphate (ATP) is a universal source of energy for any intracellular reaction. Under specific physiological or pathological conditions, ATP can be released into extracellular spaces, where it binds and activates the purinergic receptors system (i.e. P2X, P2Y and P1 receptors). Extracellular ATP (eATP) binds to P2X or P2Y receptors in immune cells, where it mediates proliferation, chemotaxis, cytokine release, antigen presentation and cytotoxicity. eATP is then hydrolyzed by ectonucleotidases into adenosine diphosphate (ADP), which activates P2Y receptors. Ectonucleotidases also hydrolyze ADP to adenosine monophosphate and adenosine, which binds P1 receptors. In contrast to P2X and P2Y receptors, P1 receptors exert mainly an inhibitory effect on the immune response. In transplantation, a prominent role has been demonstrated for the eATP/P2X7R axis; the targeting of this pathway in fact is associated with long-term graft function and reduced graft versus host disease severity in murine models. Novel P2X receptor inhibitors are available for clinical use and are under assessment as immunomodulatory agents. In this review, we will focus on the relevance of the purinergic system and on the potential benefits of targeting this system in allograft rejection and tolerance.

AB - The purine nucleotide adenosine triphosphate (ATP) is a universal source of energy for any intracellular reaction. Under specific physiological or pathological conditions, ATP can be released into extracellular spaces, where it binds and activates the purinergic receptors system (i.e. P2X, P2Y and P1 receptors). Extracellular ATP (eATP) binds to P2X or P2Y receptors in immune cells, where it mediates proliferation, chemotaxis, cytokine release, antigen presentation and cytotoxicity. eATP is then hydrolyzed by ectonucleotidases into adenosine diphosphate (ADP), which activates P2Y receptors. Ectonucleotidases also hydrolyze ADP to adenosine monophosphate and adenosine, which binds P1 receptors. In contrast to P2X and P2Y receptors, P1 receptors exert mainly an inhibitory effect on the immune response. In transplantation, a prominent role has been demonstrated for the eATP/P2X7R axis; the targeting of this pathway in fact is associated with long-term graft function and reduced graft versus host disease severity in murine models. Novel P2X receptor inhibitors are available for clinical use and are under assessment as immunomodulatory agents. In this review, we will focus on the relevance of the purinergic system and on the potential benefits of targeting this system in allograft rejection and tolerance.

KW - ATP

KW - P2X7R

KW - purinergic system

KW - rejection

UR - http://www.scopus.com/inward/record.url?scp=84896739530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896739530&partnerID=8YFLogxK

U2 - 10.1111/ajt.12567

DO - 10.1111/ajt.12567

M3 - Article

VL - 14

SP - 507

EP - 514

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -